Incyte Corp. Files Definitive Proxy Statement for 2024 Annual Meeting

Ticker: INCY · Form: DEF 14A · Filed: Apr 29, 2024 · CIK: 879169

Sentiment: bullish

Topics: proxy statement, Incyte, revenue growth, Opzelura, Jakafi

TL;DR

<b>Incyte Corporation's 2023 performance highlights significant revenue growth driven by Opzelura and Jakafi, with a strong pipeline poised for future launches.</b>

AI Summary

INCYTE CORP (INCY) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Incyte reported 14% product and royalty revenue growth in 2023, reaching $3.7 billion. Quarterly product and royalty revenues surpassed $1 billion for the first time in Q4 2023. Opzelura® (ruxolitinib) cream revenue grew 162% to $338 million in 2023. Jakafi® (ruxolitinib) net sales were $2.6 billion in 2023, an 8% increase year-over-year. The company anticipates up to ten high-impact product launches by 2030.

Why It Matters

For investors and stakeholders tracking INCYTE CORP, this filing contains several important signals. The filing details Incyte's financial performance and strategic outlook, providing stockholders with key information for upcoming voting decisions. It outlines the company's progress in drug development and commercialization, signaling potential future value creation for investors.

Risk Assessment

Risk Level: low — INCYTE CORP shows low risk based on this filing. The filing is a routine proxy statement, indicating standard corporate governance and disclosure practices with no immediate negative financial or operational red flags.

Analyst Insight

Stockholders should review the executive compensation and board proposals detailed in the proxy statement to make informed voting decisions.

Financial Highlights

revenue
3.7B
revenue Growth
14%

Revenue Breakdown

SegmentRevenueGrowth
Product and Royalty Revenues3.714%
Opzelura® (ruxolitinib) cream338162%
Jakafi® (ruxolitinib)2.68%

Key Numbers

Key Players & Entities

FAQ

When did INCYTE CORP file this DEF 14A?

INCYTE CORP filed this Proxy Statement (DEF 14A) with the SEC on April 29, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by INCYTE CORP (INCY).

Where can I read the original DEF 14A filing from INCYTE CORP?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by INCYTE CORP.

What are the key takeaways from INCYTE CORP's DEF 14A?

INCYTE CORP filed this DEF 14A on April 29, 2024. Key takeaways: Incyte reported 14% product and royalty revenue growth in 2023, reaching $3.7 billion.. Quarterly product and royalty revenues surpassed $1 billion for the first time in Q4 2023.. Opzelura® (ruxolitinib) cream revenue grew 162% to $338 million in 2023..

Is INCYTE CORP a risky investment based on this filing?

Based on this DEF 14A, INCYTE CORP presents a relatively low-risk profile. The filing is a routine proxy statement, indicating standard corporate governance and disclosure practices with no immediate negative financial or operational red flags.

What should investors do after reading INCYTE CORP's DEF 14A?

Stockholders should review the executive compensation and board proposals detailed in the proxy statement to make informed voting decisions. The overall sentiment from this filing is bullish.

Risk Factors

Key Dates

Filing Stats: 4,336 words · 17 min read · ~14 pages · Grade level 15.3 · Accepted 2024-04-29 08:24:24

Key Financial Figures

Filing Documents

Executive Compensation Highlights

Executive Compensation Highlights 15 Global Responsibility 21 Proposal 1 Election of Directors 26 Board Committees 29 Compensation of Directors 32 Corporate Governance 40 Proposal 2 Advisory Vote to Approve Executive Compensation 41

Executive Compensation

Executive Compensation 48 Compensation Discussion and Analysis 62 Compensation Committee Report 64

Executive Compensation Tables

Executive Compensation Tables 76 CEO Pay Ratio 77 Pay Versus Performance 82 Equity Compensation Plan Information 85 Report of the Audit and Finance Committee of the Board 83 Proposal 3 Ratification of Independent Registered Public Accounting Firm 86

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 88 Other Matters 90 Frequently Asked Questions A-1 Appendix A: Note Regarding Forward-Looking Statements Proxy Statement 2024 | i TABLE OF CONTENTS Proxy Statement Summary Meeting Information Time and Date: 9:00 AM EDT, June 12, 2024 Place: 1815 Augustine Cut-Off Wilmington, DE 19803 Record Date: April 15, 2024 Admission: Please follow the instructions contained in this Proxy Statement Mail Date: The Proxy Availability Notice will be mailed to stockholders on or about April 29, 2024 Voting Matters PROPOSAL BOARD'S VOTING RECOMMENDATION 1 Election of Directors FOR each Nominee 2 Advisory Vote to Approve Executive Compensation FOR 3 Ratification of Independent Registered Public Accounting Firm FOR How to Vote You may vote using any of the following methods: INTERNET TELEPHONE MAIL IN PERSON Stockholders of record may vote online at www.envisionreports.com/INCY Stockholders of record may call toll-free 1-800-652—VOTE (8683) Follow the instructions in your proxy materials. You may obtain directions to the Annual Meeting by contacting our Company's Investor Relations Department at (302) 498-6700. Proxy Statement 2024 | 1 TABLE OF CONTENTS Performance Highlights 2023 Financial Performance Incyte has consistently demonstrated strong financial execution over the past several years and in 2023, delivered another year of double-digit growth (+14%) in total product and royalty revenues to $3.7 billion. Incyte achieved a symbolic milestone in the fourth quarter with total product and royalty revenues reaching $1.0 billion for the first time. The success seen in 2023 was driven by the continued growth of Jakafi and the continued launch of Opzelura in atopic dermatitis and vitiligo. Revenues of Jakafi (ruxolitinib), our largest product by net sales, grew 8% to reach $2.6 billion for the year, with growth coming fr

Executive Compensation Highlights

Executive Compensation Highlights We have made significant progress in ensuring that our executive compensation reflects our performance. Stockholder feedback has been a key driver of the evolution of our compensation structure. Below is a comprehensive list of our compensation policies and policy enhancements made in our continuing effort to be responsive to issues discussed during our stockholder outreach and to address advice provided by stockholder advisory firms. What We Do We pay for performance, including having a total stockholder return (TSR) component for 2023 performance shares and will have 2024 performance shares based wholly on TSR We have a compensation clawback policy For 2023, 50% of executives' target equity award value was in the form of performance shares and for 2024, 60% of our CEO's and 50% of our other executives' target equity award value will be in the form of performance shares Our Compensation Committee uses an independent compensation consultant, Compensia, an

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing